Shahideh Safavi1, Derek R Robinson2, Simona Soresi1, Martin Carby1, John D Smith3. 1. Department of Transplantation, Harefield Hospital, Middlesex, UK. 2. Mathematics Department, University of Sussex, Brighton, Middlesex, UK. 3. Tissue Typing Laboratory, Heart Science Centre, Harefield Hospital, Harefield, Middlesex, UK. Electronic address: j.smith@rbht.nhs.uk.
Abstract
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the major cause of late graft failure after lung transplantation. The objective was to determine whether de novo donor human leukocyte antigen (HLA)-specific antibodies (DSA) are associated with the development of BOS or patient survival. Data were analyzed from 188 lung transplant recipients with a follow-up period up to 8 years. METHODS: HLA antibody monitoring was performed at 3-month intervals post-transplant at routine outpatient clinic attendances and during the investigation of any acute deterioration. HLA antibody data were available for 148 patients; 66 (45%) had produced HLA antibodies after transplant, of which 38 (26%) were DSA and 28 (19%) non-donor-specific HLA antibodies. RESULTS: De novo DSA was associated with development of BOS Stage 1 (BOS1; hazard ratio [HR] = 2.302, p = 0.0015), BOS2 (HR = 3.627, p < 0.0001) and BOS3 (HR = 5.736, p < 0.0001). De novo persistent DSA correlated strongly with shorter time to onset of BOS3 (HR = 6.506, p = 0.0001). There was a significant reduction in patient survival associated with de novo DSA (HR = 1.886, p = 0.047). In multivariable analyses, de novo DSA was an independent predictor for development of all stages of BOS as well as an independent predictor of poor patient survival. CONCLUSIONS: De novo DSA is a major risk factor for progression to BOS and shorter patient survival. Treatments to remove antibodies or limit antibody-mediated damage could be considered when DSA are first detected. However, a randomized, controlled trial of treatment options would enable a clearer understanding of the benefits, if any, of antibody-removal therapies.
BACKGROUND:Bronchiolitis obliterans syndrome (BOS) is the major cause of late graft failure after lung transplantation. The objective was to determine whether de novo donorhuman leukocyte antigen (HLA)-specific antibodies (DSA) are associated with the development of BOS or patient survival. Data were analyzed from 188 lung transplant recipients with a follow-up period up to 8 years. METHODS: HLA antibody monitoring was performed at 3-month intervals post-transplant at routine outpatient clinic attendances and during the investigation of any acute deterioration. HLA antibody data were available for 148 patients; 66 (45%) had produced HLA antibodies after transplant, of which 38 (26%) were DSA and 28 (19%) non-donor-specific HLA antibodies. RESULTS: De novo DSA was associated with development of BOS Stage 1 (BOS1; hazard ratio [HR] = 2.302, p = 0.0015), BOS2 (HR = 3.627, p < 0.0001) and BOS3 (HR = 5.736, p < 0.0001). De novo persistent DSA correlated strongly with shorter time to onset of BOS3 (HR = 6.506, p = 0.0001). There was a significant reduction in patient survival associated with de novo DSA (HR = 1.886, p = 0.047). In multivariable analyses, de novo DSA was an independent predictor for development of all stages of BOS as well as an independent predictor of poor patient survival. CONCLUSIONS: De novo DSA is a major risk factor for progression to BOS and shorter patient survival. Treatments to remove antibodies or limit antibody-mediated damage could be considered when DSA are first detected. However, a randomized, controlled trial of treatment options would enable a clearer understanding of the benefits, if any, of antibody-removal therapies.
Authors: Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia Journal: J Heart Lung Transplant Date: 2017-02-04 Impact factor: 10.247
Authors: Andrew M Courtwright; Severine Cao; Isabelle Wood; Hari R Mallidi; Jared Kawasawa; Anna Moniodis; Julie Ng; Souheil El-Chemaly; Hilary J Goldberg Journal: Ann Am Thorac Soc Date: 2019-09
Authors: Ramsey R Hachem; Malek Kamoun; Marie M Budev; Medhat Askar; Vivek N Ahya; James C Lee; Deborah J Levine; Marilyn S Pollack; Gundeep S Dhillon; David Weill; Kenneth B Schechtman; Lorriana E Leard; Jeffrey A Golden; LeeAnn Baxter-Lowe; Thalachallour Mohanakumar; Dolly B Tyan; Roger D Yusen Journal: Am J Transplant Date: 2018-05-15 Impact factor: 8.086
Authors: A I Dipchand; S Webber; K Mason; B Feingold; C Bentlejewski; W T Mahle; R Shaddy; C Canter; E D Blume; J Lamour; W Zuckerman; H Diop; Y Morrison; B Armstrong; D Ikle; J Odim; A Zeevi Journal: Am J Transplant Date: 2018-03-24 Impact factor: 8.086
Authors: James P Bosanquet; Chad A Witt; Bradford C Bemiss; Derek E Byers; Roger D Yusen; Alexander G Patterson; Daniel Kreisel; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem Journal: J Heart Lung Transplant Date: 2015-06-10 Impact factor: 10.247